QUESTO SITO UTILIZZA COOKIE
Con un browser aggiornato, l'esperienza sul sito Web di Medtronic sarà migliore. Aggiorna il mio browser adesso.
Si, sono un operatore sanitario
I contenuti presenti nella pagina che segue contengono informazioni rivolte esclusivamente agli OPERATORI SANITARI, in quanto si riferiscono a prodotti rientranti nella categoria dei dispositivi medici che richiedono l’impiego o l’intervento da parte di professionisti del settore medico-sanitario.
Medtronic is committed to keeping you informed about Sprint Fidelis lead performance and our ongoing vigilance efforts. We are providing a summary of the most recent performance data from our CareLink database along with updated patient management recommendations, developed with the Independent Physician Quality Panel’s guidance.
If a Fidelis pace-sense conductor fracture has occurred, we recommend implanting a new high voltage lead, with or without extraction of the Fidelis lead. It is no longer a recommended option to implant a pace-sense lead while maintaining use of the Fidelis high voltage conductors after a Fidelis pace-sense conductor fracture has occurred.
Table 1 shows the performance of the high voltage conductors of the Sprint Fidelis Model 6949 lead following a pace-sense conductor fracture. The analysis, while limited by a small sample size, indicates there is an increased risk for a high voltage conductor fracture if a pace-sense conductor fracture has previously occurred.
|Months after a Pace-Sense Conductor Fracture||0||6||12||18||21|
Patient Age: An analysis was performed by patient age, showing higher lead survival with increased patient age. This analysis was done by decade and a graph of this Model 6949 data is provided in Appendix A. Similar trends were observed for Lead Models 6931 and 6948. For patients under the age of 40, lead performance is 88.8% [+2.2/-2.7] for Model 6949, 79.5% [+3.3/-3.9] for Model 6931, and 93.6% [+3.3/-6.7] for Model 6948 at 4 years.
Patient Gender: Lead Model 6949 survival is statistically higher in male patients than female patients (p-value < 0.001), with lead survival of 91.9% [+0.5/-0.5] for men and 89.0% [+0.9/-1.0] for women at 5 years.
Device Type: No statistical difference in Lead Model 6949 performance was noted between patients with single-chamber ICDs, dual-chamber ICDs, or cardiac resynchronization therapy (CRT-D) devices.
Device Change-Out: Lead Model 6949 performance after device change-out is similar to lead performance without device change-out. Nonetheless, the Sprint Fidelis lead should be handled carefully to ensure the connector legs are not bent or stretched during a device change-out procedure.
The Lead Integrity Alert (LIA) provides three days advance notice prior to inappropriate therapy to 76% of patients with lead fractures1. As a result, we strongly recommend that all Sprint Fidelis patients who have the ability to upgrade to Lead Integrity Alert do so promptly. Also ensure that high voltage lead impedance alerts (maximum of 100 ohms) are programmed. When a lead fracture is suspected or confirmed, immediate patient attention is strongly recommended. Physicians should inform their patients to seek medical attention without delay if they experience unexpected shocks.
If a Fidelis lead fracture of any type has occurred, we recommend implanting a new high voltage lead with or without extraction of the Fidelis lead.
In patients with normal device function and no manifestation of lead fracture, no action is recommended. The risk of prophylactic intervention appears to be greater than serious injury resulting from lead fracture even for pacemaker dependent patients, except in select individual patient circumstances as determined by the physician.
In the event of a device change-out or upgrade procedure, with no manifestation of lead fracture, consider the patient age and lead model data above, as well as patient life expectancy, co-morbidities, ease of extraction related to implant time, patient preference, etc., for the following options:
The most recent Sprint Fidelis lead performance curves are available in Appendix A. Sprint Fidelis lead performance data can also be found at www.medtronic.com/fidelis and will be updated semi-annually. Medtronic’s website also has a selected list of peer-reviewed publications related to Fidelis lead performance and extraction. Medtronic is committed to answering your questions and keeping you informed. If you have any questions or concerns, please contact your Medtronic Representative or Medtronic Technical Services at 1-800-723-4636 (US).
Vice President, Quality and Regulatory
Medtronic Cardiac Rhythm Disease Management
Swerdlow C, Gunderson, B, et al. “Downloadable Algorithm to Reduce Inappropriate Shocks Caused by Fractures of Implantable Cardioverter-Defibrillator Leads”, Circulation, November 2008, 118: 2122-2129.
“Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management”, Heart Rhythm, Vol 6, No 7, July 2009.
Medtronic Italia S.p.A. Società soggetta ad attività di direzione e coordinamento da parte di Medtronic Inc.
Cap. soc. € 1.200.000,00 - Registro Imprese N. 281327 Tribunale Milano - R.E.A. N. 1275682 - Cod. Fisc./P.IVA 09238800156
Sede Legale e Uffici Via Varesina, 162 Edificio Raimondi - 20156 Milano